Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int. braz. j. urol ; 44(4): 734-739, July-Aug. 2018. tab, graf
Article in English | LILACS | ID: biblio-954089

ABSTRACT

ABSTRACT Purposes: The aim of this study was to determine the diagnostic significance of fibronectin type III domain containing protein 5 (FNDC5)/Irisin levels in the sera of patients with renal cell cancer. Materials and Methods: In the study, 48 individuals were evaluated. The patient group included 23 subjects diagnosed with renal tumor, and the control group of 25 healthy individuals. Patients diagnosed with renal tumor received surgical treatment consisting of radical or partial nephrectomy. Blood specimens were collected and serum FNDC5/Irisin and carcinoembryonic antigen (CEA) levels were determined using enzyme-linked immunosorbent assay (ELISA). Results: FNDC5/irisin and CEA levels in renal cancer patients were significantly higher compared with the control group (p=0.0001, p=0.009, respectively). Also, FNDC5 levels was more sensitive and specific than CEA levels. The best cut-off points for FNDC5/irisin were >105pg/mL and CEA were >2.67ng/mL for renal cancer. Conclusions: FNDC5/Irisin may be used as a diagnostic biomarker for renal cancer.


Subject(s)
Humans , Male , Female , Adult , Aged , Aged, 80 and over , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell/blood , Carcinoembryonic Antigen/blood , Fibronectins/blood , Kidney Neoplasms/diagnosis , Kidney Neoplasms/blood , Reference Values , Enzyme-Linked Immunosorbent Assay , Carcinoma, Renal Cell/pathology , Biomarkers, Tumor/blood , Case-Control Studies , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Statistics, Nonparametric , Neoplasm Grading , Kidney Neoplasms/pathology , Middle Aged , Neoplasm Staging
2.
Int. braz. j. urol ; 43(5): 966-973, Sept.-Oct. 2017. tab, graf
Article in English | LILACS | ID: biblio-892901

ABSTRACT

ABSTRACT Purpose: Despite the nerve-sparing technique, many patients suffer from erectile dysfunction after radical prostatectomy (RP) due to cavernous nerve injury. The aim of this study was to evaluate dipyridamole as a potential treatment agent of post-radical prostatectomy erectile dysfunction. Material and methods: A total of 18 male Sprague-Dawley rats were randomized into three experimental Groups (SHAM+DMSO, BCNI+DMSO and BCNI+DIP). An animal model of bilateral cavernous nerve crush injury (BCNI) was established to mimic the partial nerve damage during nerve-sparing RP. After creating of BCNI, dimethyl sulphoxide (DMSO) was administered transperitoneally as a vehicle to SHAM+DMSO and BCNI+DMSO Groups. BCNI+DIP Group received dipyiridamole (10mg/kg/day) as a solution in DMSO for 15 days. Afterwards, rats were evaluated for in vivo erectile response to cavernous nerve stimulation. Penile tissues were also analyzed biochemically for transforming growth factor-β1 (TGF-β1) level. Penile corporal apoptosis was determined by TUNEL method. Results: Erectile response was decreased in rats with BCNI and there was no significant improvement with dipyridamole treatment. TGF-β1 levels were increased in rats with BCNI and decreased with dipyridamole treatment. Dipyridamole led to reduced penile apoptosis in rats with BCNI and there was no significant difference when compared to sham operated rats. Conclusions: Although fifteen-day dipyridamole treatment has failed to improve erectile function in rats with BCNI, the decline in both TGF-β1 levels and apoptotic indices with treatment may be helpful in protecting penile morphology after cavernous nerve injury.


Subject(s)
Animals , Male , Rats , Prostatectomy/adverse effects , Apoptosis/drug effects , Dipyridamole/therapeutic use , Erectile Dysfunction/drug therapy , Penis/drug effects , Random Allocation , Rats, Sprague-Dawley , Disease Models, Animal , Erectile Dysfunction/etiology
3.
Int. braz. j. urol ; 43(4): 638-643, July-Aug. 2017. tab
Article in English | LILACS | ID: biblio-892869

ABSTRACT

ABSTRACT Purpose To investigate the efficacy of signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) as a novel biomarker of renal tumors. Materials and Methods 48 individuals were included in the study. The patient group (Group-1) consisted of 23 subjects diagnosed with renal tumor, and the control group (Group-2) of 25 healthy individuals. Patients diagnosed with renal tumor received surgical treatment consisting of radical or partial nephrectomy. Blood specimens were collected following overnight fasting. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1), soluble urokinase plasminogen activator receptor (suPAR) and carbonic anhydrase IX (CA IX) levels were measured from plasma samples. Patients in groups 1 and 2 were compared in terms of these biochemical parameters. Results The 23-member renal tumor group was made up of 17 (73.91%) male and 6 (26.08%) female patients with a mean age of 58.5±15.7 years (range 25 to 80). The 24-member healthy control group was made up of 16 (64%) male and 9 (36%) female subjects with a mean age of 52.4±9.12 years (range 40 to 67). Analysis revealed significant elevation in SCUBE-1 levels in the renal tumor group (p=0.005). No significant differences were detected between the groups with regard to CA IX or suPAR measurements (p=0.062 vs. p=0.176). Conclusions SCUBE-1 appears to represent a promising biomarker in the diagnosis and follow-up of patients with renal tumor.


Subject(s)
Humans , Male , Female , Adult , Aged , Aged, 80 and over , Carcinoma, Renal Cell/blood , Receptors, Urokinase Plasminogen Activator/blood , Carbonic Anhydrase IX/blood , Kidney Neoplasms/blood , Membrane Proteins/blood , Calcium-Binding Proteins , Carcinoma, Renal Cell/diagnosis , Biomarkers, Tumor/blood , Case-Control Studies , Kidney Neoplasms/diagnosis , Middle Aged
4.
Int. braz. j. urol ; 42(1): 146-153, Jan.-Feb. 2016. tab, graf
Article in English | LILACS | ID: lil-777330

ABSTRACT

ABSTRACT Purpose To investigate the protective effects against ischemia reperfusion injury of dipyridamole in a model of induced priapism in rats. Materials and Methods Twenty-four male Sprague-Dawley rats were divided into four groups, control, P/R, P/R+DMSO and P/R+D. 3ml blood specimens were collected from vena cava inferior in order to determine serum MDA, IMA, TAS, TOS and OSI values, and penile tissue was taken for histopathological examination in control group. Priapism was induced in P/R group. After 1h, priapism was concluded and 30 min reperfusion was performed. In P/R+DMSO group 1ml/kg DMSO was administered intraperitoneally 30 min before reperfusion, while in P/R+D group 10mg/kg dipyridamole was administered intraperitoneally 30 min before reperfusion. Blood and penis specimens were collected after the end of 30 min reperfusion period. Sinusoidal area (µm2), tears in tunica albuginea and injury parameters in sinusoidal endothelium of penis were investigated. Results Histopathological examination revealed no significant changes in term of sinusoidal area. A decrease in tears was observed in P/R+D group compared to P/R group (p<0.05). Endothelial injury decreased in P/R+D group compared to P/R group (p>0.05). There were no significant differences in MDA and IMA values between groups. A significant increase in TOS and OSI values was observed in P/R+D group compared to P/R group. A significant decrease in TAS levels was observed in P/R+D group compared to the P/R group. Conclusions The administration of dipyridamole before reperfusion in ischemic priapism model has a potential protective effect against histopathological injury of the penis.


Subject(s)
Animals , Male , Penis/blood supply , Priapism/prevention & control , Vasodilator Agents/pharmacology , Reperfusion Injury/prevention & control , Dipyridamole/pharmacology , Ischemia/prevention & control , Penis/pathology , Priapism/pathology , Time Factors , Penile Erection/drug effects , Serum Albumin , Biomarkers/blood , Random Allocation , Reproducibility of Results , Treatment Outcome , Oxidants/blood , Rats, Sprague-Dawley , Oxidative Stress , Ischemic Preconditioning/methods , Disease Models, Animal , Serum Albumin, Human , Malondialdehyde/blood , Antioxidants/analysis
SELECTION OF CITATIONS
SEARCH DETAIL